Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia
- To determine whether intensive glycemic control over an eight week time period will
decrease the incidence of infections from initiation of chemotherapy treatment in
patients with acute myeloid leukemia or acute lymphoblastic leukemia.
- To compare the number of episodes of infection.
- To compare the duration of neutropenia.
- To compare the number of days of bacteremia/fungemia.
- To compare the number of days of fever.
- To compare the duration of nutrition.
- To compare the duration of mucositis.
- To compare the duration of hospital stay.
- To compare the duration of antibiotic use.
- To compare the incidence of thromboembolic events.
- To compare body weight changes.
- To compare the median survival.
- To compare the remission rate with induction or salvage chemotherapy.
- To conduct comparative analysis between intervention and standard of care groups of
mean daily capillary blood glucose monitoring.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
- Arm I (intensive glycemic control): Patients with goal blood glucose 80-140 mg/dL
receive the Robert Wood Johnson University Hospital IV insulin infusion protocol to
maintain blood glucoses in the target range. Beginning 24 hours after maintenance of
oral or enteral feedings patients receive an intensive regimen of insulin glargine and
insulin glulisine (Apidra™) subcutaneously for 4 weeks as needed. Patients may also
receive insulin in the total parenteral nutrition (TPN) mixture.
- Arm II (standard care control): Patients with goal blood glucose < 250 mg/dL are
started on subcutaneous insulin sliding scale at the discretion of the treating
physician with blood glucose monitoring and adjustment according to the insulin sliding
scale. Insulin may also be added to TPN if needed at the investigator's discretion.
After completion of study treatment, patients are followed up for 4 weeks.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Incidence of new infections
Mecide Gharibo, MD
Cancer Institute of New Jersey
United States: Institutional Review Board
|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School||New Brunswick, New Jersey 08903|